OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic …

Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from ...

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...
Seeking Alpha

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

Dialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy NEW YORK--(BUSINESS WIRE)-- OS Therapies (OSTX) (“OS ...
ascopubs.org

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric ...

Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...
Healio

‘A big deal’: Discovery of new genetic link to osteosarcoma opens ‘window of opportunity’

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
EurekAlert!

Veratramine: A potential candidate against osteosarcoma

Osteosarcoma (OS) is a common bone malignancy that primarily affects adolescents and young adults and has an early propensity for metastasis. Given that current chemotherapeutic approaches cause ...